115 related articles for article (PubMed ID: 8283086)
21. Experimental research with synthetic copolymer-coated cardiopulmonary bypass circuits: inflammatory and thrombogenicity analysis.
Gabriel EA; Montevilla FM; Chida VV; Dias FN; Montoya CV; Otsubo H; Pires ZF; Nogaroto SL
Artif Organs; 2012 Jan; 36(1):110-4. PubMed ID: 21848861
[TBL] [Abstract][Full Text] [Related]
22. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
Sundaram S; Gikakis N; Hack CE; Niewiarowski S; Edmunds LH; Koneti Rao A; Sun L; Cooper SL; Colman RW
Thromb Haemost; 1996 Jan; 75(1):76-82. PubMed ID: 8713783
[TBL] [Abstract][Full Text] [Related]
23. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators.
von Segesser LK; Turina M
J Thorac Cardiovasc Surg; 1989 Sep; 98(3):386-96. PubMed ID: 2770320
[TBL] [Abstract][Full Text] [Related]
24. A reevaluation of heparin requirements for cardiopulmonary bypass.
Cardoso PF; Yamazaki F; Keshavjee S; Schaefers HJ; Hsieh CM; Wang LS; Glynn MF; Patterson GA; Cooper JD
J Thorac Cardiovasc Surg; 1991 Jan; 101(1):153-60. PubMed ID: 1986159
[TBL] [Abstract][Full Text] [Related]
25. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
26. A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy.
Ikuta T; Fujii H; Shibata T; Hattori K; Hirai H; Kumano H; Suehiro S
Ann Thorac Surg; 2004 May; 77(5):1678-83. PubMed ID: 15111165
[TBL] [Abstract][Full Text] [Related]
27. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
Horimoto H; Kondo K; Asada K; Sasaki S
Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
[TBL] [Abstract][Full Text] [Related]
28. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
Thelin S; Bagge L; Hultman J; Borowiec J; Nilsson L; Thorelius J
Eur J Cardiothorac Surg; 1991; 5(9):486-91. PubMed ID: 1931093
[TBL] [Abstract][Full Text] [Related]
29. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
Kikura M; Tanaka K; Hiraiwa T; Tanaka K
J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
[TBL] [Abstract][Full Text] [Related]
30. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
32. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
33. Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces.
Palatianos GM; Dewanjee MK; Smith W; Novak S; Hsu LC; Kapadvanjwala M; Sfakianakis GN; Kaiser GA
ASAIO Trans; 1991; 37(4):620-2. PubMed ID: 1722689
[TBL] [Abstract][Full Text] [Related]
34. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
[TBL] [Abstract][Full Text] [Related]
35. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
[TBL] [Abstract][Full Text] [Related]
36. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
Wakayama S; Suzuki T; Sakai T; Matsuki A
Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
[TBL] [Abstract][Full Text] [Related]
37. [Thrombosis-resistant heparin-coated diffusion membrane oxygenators: an experimental study].
Tkebuchava T; von Segesser LK; Leskosek B; Pei P; Turina M
Swiss Surg Suppl; 1996; Suppl 1():36-40. PubMed ID: 8653573
[TBL] [Abstract][Full Text] [Related]
38. Platelet involvement in the activated coagulation time of heparinized blood.
Moorehead MT; Westengard JC; Bull BS
Anesth Analg; 1984 Apr; 63(4):394-8. PubMed ID: 6367544
[TBL] [Abstract][Full Text] [Related]
39. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
